FDA Accepts Bayerās BETACONNECT License Application for Relapsing-Remitting Multiple Sclerosis
Bayer HealthCareĀ recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT forĀ the treatment of relapsing-remitting multiple sclerosis (MS). BETACONNECT isĀ a new drug delivery option…